當代置業(01107.HK)多個系列優先票據建議修訂獲必要同意
當代置業(01107.HK)公布,就2023年到期的7%與9%優先票據、2024年到期的8%與10%優先票據、2025年到期的9%與11%優先票據、2026年到期的9%與11%優先票據及2027年到期的9%與11%優先票據,截至2023年12月18日,已獲得就各契約建議修訂所需的有關各系列票據的必要同意,預料待同意徵求聲明所載條件達成或獲豁免後,公司將於本周五(22日)或前後簽立補充契約,並支付適用同意費。
公司表示,將在切實可行的情況下,盡快發出與同意徵求聲明中規定的形式基本相同的贖回通知,以用2023年新票據實物支付贖回所有未償還的2023年票據,預期將於本月29日或前後進行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.